Get the Stockscreener App
5.30
1.12%
-0.06
After Hours:
5.23
-0.07
-1.32%
Intensity Therapeutics Inc stock is traded at $5.30, with a volume of 23,880.
It is down -1.12% in the last 24 hours and down -21.83% over the past month.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
See More
Previous Close:
$5.36
Open:
$5.24
24h Volume:
23,880
Relative Volume:
0.49
Market Cap:
$13.46M
Revenue:
-
Net Income/Loss:
$-11.61M
P/E Ratio:
-0.8357
EPS:
-6.3418
Net Cash Flow:
$-9.23M
1W Performance:
-3.64%
1M Performance:
-21.83%
6M Performance:
-23.47%
1Y Performance:
-88.90%
1-Day Range:
$5.17
$5.44
1-Week Range:
$5.14
$5.75
52-Week Range:
$4.6325
$50.00
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
5.30 | 13.62M | 0 | -11.61M | -9.23M | -6.3418 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation - PR Newswire
Support Test: Can Intensity Therapeutics Inc disrupt its industryGap Down & Long-Term Safe Investment Ideas - baoquankhu1.vn
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart
Intratumoral Cancer Therapies Market: Expanding Revenue - openPR.com
Update Report: Is Intensity Therapeutics Inc likely to announce a buybackQuarterly Investment Review & Comprehensive Market Scan Reports - baoquankhu1.vn
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Aug Technicals: Does Intensity Therapeutics Inc have a competitive edge2026 Trends & Expert Approved Trade Ideas - baoquankhu1.vn
Aug Fed Impact: Can Intensity Therapeutics Inc benefit from deglobalization2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
RSI Check: What are Intensity Therapeutics Incs recent SEC filings showingPortfolio Update Summary & Weekly Sector Rotation Insights - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE) - The Globe and Mail
Hedge Fund Bets: What are Intensity Therapeutics Incs recent SEC filings showingMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Risk Analysis: What is Intensity Therapeutics Incs debt to equity ratio2026 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Intensity Therapeutics (INTS) CEO receives 37,749-share stock bonus grant - Stock Titan
U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation - The Globe and Mail
Why Did INTS Stock Plummet 25% Today? - Dailyhunt
Short Squeeze: Is Intensity Therapeutics Inc stock a top performer YTD2026 Momentum & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Intensity Therapeutics, Inc. 2025 Annual Report: Innovative Intratumoral Cancer Drug Development and Clinical Pipeline Overview - Minichart
INTS: Promising clinical results and strong 2025 capital raise extend cash runway into Q2 2027 - TradingView
Clinical data and cash runway update for Intensity Therapeutics (NASDAQ: INTS) - Stock Titan
[10-K] INTENSITY THERAPEUTICS, INC. Files Annual Report - Stock Titan
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - ChartMill
INTS: Paused clinical trials and ongoing losses highlight urgent need for new funding - TradingView
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Market Pulse: Can Fury Gold Mines Limited expand its profit marginsEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Intensity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
US Market Recap: Does Intensity Therapeutics Inc have strong EBITDA margins2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn
Intensity Therapeutics receives new US patent for cancer treatment By Investing.com - Investing.com Australia
Intensity Therapeutics Expands ATM Equity Offering Capacity - The Globe and Mail
Intensity Therapeutics issued new patent in the US - TipRanks
Intensity Therapeutics receives new US patent for cancer treatment - Investing.com
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US - Finviz
Intensity Therapeutics Inc increases ATM offering capacity to $60 million on March 23, 2026SEC filing - marketscreener.com
Intensity Therapeutics IncIncreases ATM Offering Capacity To $60 Million On March 23, 2026SEC Filing - tradingview.com
Intensity Therapeutics boosts ATM capacity to $60.0M to enhance financing flexibility - TradingView
Intensity Therapeutics (NASDAQ: INTS) boosts $60M at-the-market capacity - Stock Titan
Intensity Therapeutics (NASDAQ: INTS) raises ATM capacity to $60M - Stock Titan
If You Invested $1,000 in INTENSITY THERAPEUTICS INC (INTS) - Stock Titan
Is Intensity Therapeutics Inc currently under institutional pressure2026 Trends & High Win Rate Trade Tips - baoquankhu1.vn
Block Trades: Is Intensity Therapeutics Inc currently under institutional pressureWeekly Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Technical Analysis: Is Intensity Therapeutics Inc stock a top performer YTD2026 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn
Aug Rallies: Should I set a stop loss on Intensity Therapeutics Inc2026 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Forecast Cut: Can Intensity Therapeutics Inc ride the EV waveWeekly Profit Analysis & Technical Entry and Exit Alerts - baoquankhu1.vn
Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement - MSN
Intensity Therapeutics reports early trial data in breast cancer - Investing.com Nigeria
Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS) - The Globe and Mail
Intensity Therapeutics updates breast cancer trial, files to resume enrollment following study pause - MSN
Intensity Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria
Alliance Global Partners Sticks to Their Buy Rating for Intensity Therapeutics, Inc. (INTS) - The Globe and Mail
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
Intensity Therapeutics price target adjusted to $30 at Alliance Global - TipRanks
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):